Patent on Product for Treating Respiratory Disease Issued to Milkhaus Laboratory
09:16 a.m. Mar 10, 1998 Eastern

BOXFORD, Mass.--(BW HealthWire)--March 10, 1998--Milkhaus Laboratory Inc., a clinical stage biopharmaceutical company, announced today that it had been issued a patent on its investigational agent for the treatment of pulmonary diseases.

Pulmonary disease are characterized by bronchial or sinus congestion and may be accompanied by the production of large amounts of sputum. Those conditions lead to bacterial infection, often requiring antibiotic therapy. Such diseases include cystic fibrosis, bronchitis, emphysema, sinusitis and the common cold.

Dr. John McMichael, CEO of Milkhaus Laboratory Inc. said: "Perhaps the most serious of the respiratory diseases is cystic fibrosis. Our product, called HP-3, employs nucleic acid in a novel way. It works to break up sputum, and because cystic fibrosis involves the production of large amounts of that viscous material, we regard its treatment as the most challenging of the chronic obstructive pulmonary diseases. Last year, we initiated an FDA-approved clinical trial to evaluate HP-3 for patients with cystic fibrosis. That double-blind placebo-controlled trial should be completed mid-year. Further clinical evaluations of HP-3 in patients with chronic bronchitis and emphysema are planned for initiation in 1998."

Milkhaus Laboratory Inc. has established a broad patent position for its signaling technology. Additional IND-based clinical trials for other therapeutic products are underway for benign prostatic hypertrophy ("BPH"), leukemia, myelodysplastic syndrome and prostate cancer. (See also: http://www.businesswire.com)

Copyright 1998, Business Wire

Volver a Medios de Comunicación